Humana Swaps Private Equity for BlackRock in $2.8bn CenterWell Deal
Humana has handed majority ownership of its roughly 150 CenterWell senior primary care clinics to BlackRock in a $2.8bn transaction that reorganises how the insurer finances its fastest-growing care business. Announced on 13 October 2026, the deal installs funds managed by HPS Investment Partners, BlackRock's private credit arm, as majority owner of a new joint venture, with CenterWell holding a minority stake and continuing to run every clinic day to day.
What has Humana actually agreed with BlackRock?
The new venture replaces the joint ventures Humana ran with Welsh, Carson, Anderson & Stowe, the private equity firm that spent the past seven years helping to build CenterWell into one of the largest senior-focused, value-based primary care networks in the United States. BlackRock is buying out WCAS's equity, valued at about $2.8bn, on revised terms that reflect a more mature business than the one the original ventures were structured around.
Over the next two years, the partners plan to deploy fresh capital to fund existing clinics, open new sites, and expand through acquisitions. From 2028, CenterWell can begin buying clinics back from the venture at its own election. If it has not reacquired all of them by the end of 2033, BlackRock can trigger a sale process for whatever remains, with CenterWell holding the right to make the first offer. The transaction is expected to close in the fourth quarter of 2026, subject to state and federal regulatory approval, and Humana has reaffirmed its 2026 adjusted earnings guidance of at least $9.00 per share, which the deal is not expected to move.
Sanjay Shetty, president of CenterWell, framed the arrangement as a continuation of the same senior-focused care model under a new financial partner, and credited the outgoing WCAS team for its role in scaling the business.
Why is Humana restructuring CenterWell now?
The timing sits against a bruising two years in Humana's core Medicare Advantage business. The insurer's share of members in plans rated four stars or higher fell from 94% in 2024 to 25% in 2025 and then 20% for 2026, a slide that by some estimates cost the company more than $1bn in quality bonus payments and pushed it to exit plans covering roughly 600,000 members for 2027. The Centers for Medicare & Medicaid Services released 2027 star ratings on 9 October 2026, and Humana's position rebounded sharply, with about 95% of its members back in four-star-or-higher plans, restoring a critical revenue lever just days before the BlackRock deal was unveiled.
Against that backdrop, the restructuring is first a balance sheet exercise. Humana has said it expects the new venture to deliver greater financial flexibility, additional growth capital, and a lower cost of capital. It follows a $900m agreement in June 2026 to sell Humana's minority stake in Gentiva, the hospice provider carved out of its former Kindred at Home business, to a consortium that also included BlackRock. Together the two deals mark a deliberate simplification of Humana's portfolio around insurance and CenterWell.
What is the catch in the balance sheet story?
The headline benefit is the removal of a put option that let the legacy WCAS ventures sell their stake back to Humana, an arrangement that sat on the balance sheet as a liability. Stripping it out is the main source of the "enhanced balance sheet efficiency" the company is advertising.
The replacement is not free of obligations. According to Humana's 8-K filing with the Securities and Exchange Commission, CenterWell has agreed to certain minimum return protections for BlackRock, which create a derivative instrument of their own. One form of downside guarantee has, in effect, been recast as another. For analysts modelling Humana's leverage, the open question is whether the net effect genuinely lowers the company's cost of capital once those protections are priced in, or whether it mainly shifts the liability into a less visible line.
How does this fit private credit's push into healthcare?
For finance professionals, the identity of the buyer is the story. HPS Investment Partners manages about $197bn in assets and ranked among the largest private credit firms in the world before BlackRock acquired it in 2025, folding it into a combined private credit unit overseeing roughly $220bn in client assets. Deploying that capital into the ownership of physical care infrastructure, rather than lending against it, shows how far private credit has travelled from corporate loans into the real economy.
It is also BlackRock's second healthcare transaction with Humana this year, after the Gentiva sale. Private capital has underwritten the value-based care build-out for more than a decade, but the move from a traditional buyout sponsor such as WCAS to a private credit heavyweight such as BlackRock signals where the balance of financial power in the sector now sits.
Where does this leave CenterWell against Optum and CVS?
CenterWell competes in a value-based senior primary care market that Humana's former chief executive, Bruce Broussard, once sized at about $700bn. Its largest rival is Optum, the care-delivery arm of UnitedHealth Group and one of the biggest employers of physicians in the country. CVS Health bought Oak Street Health for $10.6bn in 2023, and Walgreens built out VillageMD with a multibillion-dollar investment, as payers and retailers raced to own the clinics that treat their most expensive members.
Humana's approach is structurally different. Rather than consolidating clinics onto its own balance sheet, as CVS and UnitedHealth have, it keeps operational control while outsourcing the capital intensity to an external financier, first private equity and now private credit. That lets CenterWell keep expanding without the full weight of ownership landing on Humana's accounts, at the cost of sharing the upside and guaranteeing a minimum return to its new partner.
Guggenheim Securities advised Humana as lead financial adviser, with Goldman Sachs also acting as financial adviser and Fried, Frank, Harris, Shriver & Jacobson providing legal counsel.
Why This Matters to FinanceX Readers
Humana's deal is a live case study in how private credit is becoming the balance sheet partner of choice for stressed public companies. A health insurer recovering from a ratings shock has chosen BlackRock, rather than a bank or the public markets, to help finance and expand a core asset while moving it off its own books. For investors, the signal is twofold: watch whether the new minimum-return protections actually reduce Humana's cost of capital as advertised, and watch how aggressively private credit managers push from lending into owning the infrastructure of healthcare, real estate, and other hard assets. The boundary between asset manager and operating-company financier is thinning, and Humana has just given it a $2.8bn test.
